Advertisement
Research Brief|Articles in Press

Association of Smokeless Tobacco Use With Incident Peripheral Artery Disease: Results From the Atherosclerotic Risk in Communities Study

Published:January 21, 2023DOI:https://doi.org/10.1016/j.amepre.2023.01.001

      Introduction

      Cigarette smoking is associated with an increased risk for peripheral artery disease. It is unknown whether smokeless tobacco, a noncombustible form of tobacco exposure, is also associated with increased peripheral artery disease risk. Using data from the Atherosclerosis Risk in Communities study, we tested the hypothesis that the use of smokeless tobacco is associated with a higher risk of developing peripheral artery disease.

      Methods

      Participants with peripheral artery disease at baseline were excluded. Smokeless tobacco use was assessed 3 times from 1987 to 1995, and peripheral artery disease events accrued from 1987 to 2018. Smokeless tobacco was modeled as a time-dependent exposure in Cox regression models. Analyses were completed in 2021.

      Results

      This study included 14,344 participants with a baseline mean (SD) age of 54.1 (5.7) years; 54.8% were female, and 26.4% were Black. There were 635 incident peripheral artery disease events over a median follow-up of 27.6 years (maximum of 32.1 years). The peripheral artery disease incidence rate was 4.44 per 1,000 person-years among those who used smokeless tobacco compared with 1.74 per 1,000 person-years for those who did not. The hazard ratio for current versus never smokeless tobacco use was 1.94 (95% CI=1.31, 2.88) after adjustment for sociodemographic characteristics and cigarette smoking. Peripheral artery disease incidence rate among those currently using smokeless tobacco was similar to that of those who currently smoke cigarette (3.39 per 1,000 person-years).

      Conclusions

      Current smokeless tobacco use was associated with high rates of peripheral artery disease, similar to cigarette smoking. Future research should evaluate the effect of cessation of noncombustible tobacco on incident peripheral artery disease.

      INTRODUCTION

      Peripheral artery disease (PAD) affects over 200 million people worldwide
      • Fowkes FG
      • Rudan D
      • Rudan I
      • et al.
      Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis.
      and is associated with mortality and comorbid cardiovascular disease (CVD).
      • Diehm C
      • Allenberg JR
      • Pittrow D
      • et al.
      Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease.
      Cigarette smoking increases the risk for all CVD, but the strongest association is with PAD.
      • Ding N
      • Sang Y
      • Chen J
      • et al.
      Cigarette smoking, smoking cessation, and long-term risk of 3 major atherosclerotic diseases.
      Public health efforts have successfully reduced cigarette smoking in the U.S. over the past 30 years; however, smokeless tobacco use may be increasing.
      • Wang TW
      • Kenemer B
      • Tynan MA
      • Singh T
      • King B.
      Consumption of combustible and smokeless tobacco — United States, 2000–2015.
      On the basis of data from the National Health Interview Survey, an estimated 2.4% of adults used smokeless tobacco in 2019.
      • Cornelius ME
      • Wang TW
      • Jamal A
      • Loretan CG
      • Neff LJ.
      Tobacco product use among adults — United States, 2019.
      When people use smokeless tobacco products, they are not inhaling the noxious products of combustion that are produced by a burning cigarette. Yet, smokeless tobacco causes nicotine exposure and may adversely impact vascular health by raising blood pressure and cholesterol and increasing oxidative stress.
      • Gupta R
      • Gurm H
      • Bartholomew JR.
      Smokeless tobacco and cardiovascular risk.
      Similar to cigarette smoking, chewing tobacco and snuff is linked to increased risk for heart disease and stroke,
      • Yatsuya H
      • Folsom AR
      • Investigators ARIC
      Risk of incident cardiovascular disease among users of smokeless tobacco in the atherosclerosis risk in communities (ARIC) study.
      ,
      • Henley SJ
      • Thun MJ
      • Connell C
      • Calle EE.
      Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States).
      but the impact on PAD is unclear. We tested the hypothesis that the use of smokeless tobacco is associated with a greater risk of incident PAD among participants of the Atherosclerosis Risk in Communities (ARIC) Study.

      METHODS

      The ARIC study is a longitudinal community-based cohort study that recruited 15,792 adults aged 45–64 years at the Visit 1 baseline (1987–89) from 4 sites in the U.S.
      • Wright JD
      • Folsom AR
      • Coresh J
      • et al.
      The ARIC (atherosclerosis risk in communities) study: JACC focus Seminar 3/8.
      IRBs at each site approved the study protocol, and participants provided written informed consent. After excluding participants with prevalent PAD at baseline (ankle‒brachial index≤0.90 [n=632]), intermittent claudication (n=93), and missing data (n=723), our final analytic sample included 14,344 participants.
      As detailed in the Appendix (available online), the use of smokeless tobacco (specifically chewing tobacco and/or snuff) and cigarettes was self-reported at Visits 1, 2 (1990–1992), and 3 (1993–1995). Smokeless tobacco and cigarette smoking were categorized at each visit as current, former, or never use. Information on other covariates was collected at baseline using standard ARIC procedures.
      The primary outcome for this analysis was incident PAD through 2018. This was characterized by hospital admission for PAD, leg amputation, or leg revascularization procedures as identified by the International Classification of Diseases, Ninth Revision or ICD-10 administrative codes (Appendix Table 1, available online).
      Table 1Participant Characteristics by Smokeless Tobacco Status at Baseline, the Atherosclerosis Risk in Communities Study, 1987–1989
      Use of smokeless tobacco
      CharacteristicsTotal sample (N=14,344)Never (n=13,104)Former (n=754)Current (n=486)
      Sociodemographics
       Age, years54.1±5.754.0±5.755.2±5.855.1±5.7
       Male sex, %45.241.982.475.9
       Black race, %26.425.336.238.5
       Total annual household income <$16,000, %22.321.033.140.0
       Less than high school education, %25.823.743.051.9
      Tobacco exposures
       Currently smokes cigarettes, %25.324.933.723.7
       Formerly smoked cigarettes, %32.531.150.841.9
       Never smoked cigarettes, %42.244.015.534.4
       Exposure to second-hand smoke, hours/week10.6±18.210.4±18.012.9±20.913.1±19.5
      Other behaviors
       Usual ethanol intake, g/week41.2±94.142.1±95.558.3±116.650.1±106.4
       Weekly leisure activity, hours2.36±0.572.4±0.62.3±0.62.2±0.6
      Physiologic indicators
       Cardiovascular disease history, %6.25.89.911.5
       Hypertension, %34.133.539.242.9
       Diabetes mellitus, %11.510.916.420.6
       Kidney disease, %1.11.11.51.7
       BMI, kg/m227.7±5.327.6±5.328.1±4.928.9±5.5
       Systolic blood pressure, mmHg120.9±18.6120.8±18.5123.4±19.1124.4±19.9
       Low-density lipoprotein cholesterol level, IU/L3.5±1.03.5±1.03.5±1.03.7±1.0
       Use of antihypertensive medication, %29.929.432.938.5
       Use of cholesterol-lowering medication, %2.82.64.43.1
      Note: Values are reported as a percent or mean ± SD. To assess for differences in characteristics by baseline smokeless tobacco status, we used ANOVA for continuous variables and chi-square for categorical variables. There was a significant difference in all characteristics by smokeless tobacco status (p≤0.01), except for kidney disease (p=0.34) and low-density lipoprotein cholesterol (p=0.90). Cardiovascular disease included coronary heart disease and stroke. Detailed descriptions of these conditions are available in the Appendix (available online). Hypertension was defined as systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg, or the use of antihypertensive medication in the past 2 weeks; diabetes mellitus was defined as fasting glucose ≥126 mg/dL, nonfasting glucose ≥200 mg/dL, the use of diabetes medications in the past 2 weeks, or self-reported physician diagnosis of diabetes; and kidney disease was defined as eGFR <60 mL/min per 1.73 m2.
      eGFR, estimated glomerular filtration rate.
      Participant characteristics were compared by baseline smokeless tobacco use. Cox proportional hazards regression models were used to evaluate the association between smokeless tobacco exposure and incident PAD independent of cigarette smoking (primary model) and CVD risk factors. In the Cox models, smokeless tobacco and cigarette smoking were both modeled as time-dependent exposures at Visits 1–3 (Appendix, available online, for details). Baseline values were used for all other covariates. Interactions by race, sex, and cigarette smoking status were assessed. SAS, Version 9.4, was used (SAS Institute Inc., Cary, NC). Analyses were conducted in 2021.

      RESULTS

      The mean (SD) age for the sample at baseline was 54.1 (5.7) years; 54.8% were female, and 26.4% were Black. As shown in Table 1, 3% (486 of 14,344) of participants used smokeless tobacco at Visit 1. Of those currently using smokeless tobacco, 75.9% were male, and there were higher proportions of Black participants (38.5% vs 25.3%), those with low income (40.0% vs 21.0%), and those with less than high school education (51.9% vs 23.7%) than among those with never use. Nearly two thirds of participants currently using smokeless tobacco currently or formerly smoked cigarettes.
      There were 635 incident PAD events over a median follow-up of 27.6 years (maximum of 32.1 years). The PAD incidence rate for current versus never smokeless tobacco use at baseline was 4.44 and 1.74 per 1,000 person-years, respectively (Table 2). The hazard ratio (HR) for current versus never smokeless tobacco use was 1.83 (95% CI=1.25, 2.66) after adjustment for sociodemographic characteristics. In the primary model, the HR remained statistically significant after adjustment for cigarette smoking at Visits 1–3 (1.94; 95% CI=1.31, 2.88). PAD risk was similar after adjustment for CVD and CVD risk factors (HR=2.12; 95% CI=1.41, 3.18). There were no interactions by race or sex. Results were similar in a sensitivity analysis incorporating competing risks of death (Appendix Table 2, available online).
      Table 2Incidence Rates and Hazard Ratios for PAD Associated With Smokeless Tobacco Use, ARIC Study, 1987–2018
      Hazard ratio for incident PAD (95% CI)
      Tobacco exposuresPAD events,nIncidence rate (per 1,000 PY)CrudeModel 1Model 2Model 3
      A time-varying exposure variable was used for cigarette smoking through ARIC Visits 1, 2, and 3 in the overall analysis. Baseline cigarette smoking status was used in the stratified analyses.
      Model 4
      Smokeless tobacco use
      A time-varying exposure variable was used for smokeless tobacco through ARIC Visits 1, 2, and 3. ARIC, Atherosclerosis Risk in Communities; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PAD, peripheral artery disease; PY, person-years.
      (total)
       Never5421.74RefRefRefRefRef
       Former503.111.75

      (1.28, 2.41)
      1.37

      (0.99, 1.90)
      1.25

      (0.90, 1.73)
      1.12

      (0.78, 1.61)
      1.09

      (0.75, 1.58)
       Current434.442.81

      (1.98, 4.00)
      2.34

      (1.63, 3.35)
      1.83

      (1.25, 2.66)
      1.94

      (1.31, 2.88)
      2.12

      (1.41, 3.18)
      Stratified analyses
       Former/never cigarette smokers (n=10,716)
       Smokeless tobacco
      A time-varying exposure variable was used for smokeless tobacco through ARIC Visits 1, 2, and 3. ARIC, Atherosclerosis Risk in Communities; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PAD, peripheral artery disease; PY, person-years.
      use
        Never3191.31RefRefRefRefRef
        Former282.511.92

      (1.27, 2.89)
      1.40

      (0.92, 2.13)
      1.24

      (0.81, 1.89)
      1.31

      (0.84, 2.03)
       Current344.484.04

      (2.70, 6.04)
      3.28

      (2.17, 4.95)
      2.60

      (1.70, 3.98)
      2.76

      (1.76, 4.30)
      Current cigarette smokers (n=3,628)
       Smokeless tobacco
      A time-varying exposure variable was used for smokeless tobacco through ARIC Visits 1, 2, and 3. ARIC, Atherosclerosis Risk in Communities; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PAD, peripheral artery disease; PY, person-years.
      use
        Never2233.28RefRefRefRefRef
      Former224.461.36

      (0.82, 2.27)
      1.20

      (0.71, 2.03)
      1.23

      (0.72, 2.08)
      1.09

      (0.62, 1.92)
        Current94.291.18

      (0.56, 2.51)
      1.06

      (0.50, 2.28)
      0.85

      (0.37, 1.95)
      0.98

      (0.43, 2.26)
      Note: Boldface indicates statistical significance (p<0.05).
      Model 1 (demographic factors): age, sex, and race/ARIC site. Model 2 (socioeconomic factors): Model 1 + education and income. Model 3 (primary model, assessing independence from cigarette smoking): Model 2 + cigarette smoking. Model 4 (cardiovascular risk factors, likely includes both confounding and mediating factors): Model 3 + BMI, alcohol intake, leisure activity level, coronary heart disease, stroke, diabetes, systolic blood pressure, antihypertensive medication use, LDL cholesterol, HDL cholesterol, cholesterol-lowering medication, and kidney function. Incidence rates are unadjusted.
      a A time-varying exposure variable was used for cigarette smoking through ARIC Visits 1, 2, and 3 in the overall analysis. Baseline cigarette smoking status was used in the stratified analyses.
      b A time-varying exposure variable was used for smokeless tobacco through ARIC Visits 1, 2, and 3.ARIC, Atherosclerosis Risk in Communities; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PAD, peripheral artery disease; PY, person-years.
      Baseline cigarette smoking status modified the association between smokeless tobacco and incident PAD (p-interaction=0.03). Compared with no smokeless tobacco use, current use was associated with incident PAD among those who never/formerly smoked cigarettes in all regression models (fully adjusted HR=2.76; 95% CI=1.76, 4.30) but not among those who were currently smoking (fully adjusted HR=0.98; 95% CI=0.43, 2.26) (Table 2). When stratified by smokeless tobacco and cigarette use, PAD incidence rate was similar for those currently using smokeless tobacco and those currently smoking cigarette (Figure 1).
      Figure 1
      Figure 1Incidence rate for peripheral artery disease associated with the use of smokeless tobacco at baseline, stratified by baseline smoking status, the Atherosclerosis Risk in Communities Study, 1987–2018.
      PAD, peripheral artery disease.

      DISCUSSION

      In this community-based study, the use of smokeless tobacco was associated with a twofold increased risk for incident PAD compared with never use, after adjustment for sociodemographic characteristics, cigarette smoking, and other CVD risk factors. The PAD incidence rate was similar among participants currently using smokeless tobacco and those currently smoking cigarette. Elevated PAD risk associated with smokeless tobacco was present for participants who reported former or never smoking at baseline but not for those currently smoking.
      There appear to have been no previous studies on whether smokeless tobacco increases PAD risk. Previous research on smokeless tobacco and other manifestations of CVD has yielded mixed findings.
      • Piano MR
      • Benowitz NL
      • Fitzgerald GA
      • et al.
      Impact of smokeless tobacco products on cardiovascular disease: implications for policy, prevention, and treatment: a policy statement from the American Heart Association.
      ,
      • Vidyasagaran AL
      • Siddiqi K
      • Kanaan M.
      Use of smokeless tobacco and risk of cardiovascular disease: A systematic review and meta-analysis.
      An ARIC study previously showed that smokeless tobacco use elevated the risk for heart disease and stroke.
      • Yatsuya H
      • Folsom AR
      • Investigators ARIC
      Risk of incident cardiovascular disease among users of smokeless tobacco in the atherosclerosis risk in communities (ARIC) study.
      Our study extends these findings to include increased risk for PAD. The lack of any association of smokeless tobacco with PAD for those currently smoking is likely due to the overwhelming PAD risk associated with cigarette smoking that persists even after smoking cessation. Ding et al. showed that people who stopped smoking remained at higher risk for PAD for up to 30 years after cessation.
      • Ding N
      • Sang Y
      • Chen J
      • et al.
      Cigarette smoking, smoking cessation, and long-term risk of 3 major atherosclerotic diseases.
      Whether cessation of smokeless tobacco use might reduce PAD risk is unknown.
      Our definition of smokeless tobacco was limited to chewing tobacco and snuff because these were the main smokeless methods in the late 1980s when ARIC started. However, smokeless tobacco can be viewed as an analog to E-cigarette products because neither involves combustion in their use. Noncombustible nicotine and tobacco products have been perceived as clean nicotine delivery systems and therefore less harmful than cigarette smoking, leading some to advocate for their use to help with cigarette cessation. The U.S. Food and Drug Administration recently authorized the marketing of some tobacco-flavored E-cigarette products to aid cessation efforts while denying others.

      FDA permits marketing of E-cigarette products, marking first authorization of its kind by the agency. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-e-cigarette-products-marking-first-authorization-its-kind-agency. Updated December 12, 2021. Accessed September 27, 2022.

      ,

      FDA denies authorization to market JUUL products. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-denies-authorization-market-juul-products. Updated June 23, 2022. Accessed September 27, 2022.

      Uncertainty about the net benefit versus harm of E-cigarettes remains.
      • Pechacek TF.
      Can e-cigarettes help adults who smoke successfully quit all combusted tobacco products?.
      This study adds to the growing body of research showing the CVD risk associated with some forms of noncombustible nicotine and tobacco exposure. The strengths of this study include a relatively large number of PAD events experienced among community-dwelling Black and White individuals, analysis with robust adjustment, and testing of interaction by cigarette smoking.

      Limitations

      Limitations include self-report of smokeless tobacco use, but self-report has been shown to be reasonably accurate when compared with serum cotinine.
      • Agaku IT
      • King BA.
      Validation of self-reported smokeless tobacco use by measurement of serum cotinine concentration among U.S. adults.
      Second, we lacked information about participants’ initiation or cessation of smokeless tobacco use after ARIC Visit 3, which may have led to exposure misclassification. Third, PAD incidence was determined by hospitalization only, potentially missing milder diseases diagnosed as outpatient (uncertain about whether missed PAD diagnoses would vary by smokeless tobacco status). Finally, causal inference is limited owing to the observational design.

      CONCLUSIONS

      Current smokeless tobacco use was associated with a twofold risk of developing PAD in the community-based ARIC sample. PAD incidence rates were similar for those using smokeless tobacco and those smoking cigarettes (4.44 per 1,000 people vs 3.39 per 1,000 person-years). Additional research should specifically examine the risk of PAD associated with contemporary forms of noncombustible tobacco, particularly E-cigarettes, and evaluate whether cessation of noncombustible tobacco reduces PAD risk.

      ACKNOWLEDGMENTS

      The authors thank the staff and participants of the Atherosclerosis Risk in Communities study for their important contributions.
      The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, NIH, Department of Health and Human Services under contract Numbers 75N92022D00001, 75N92022D00002, 75N92022D00003, 75N92022D00004, and 75N92022D00005. GH is deceased.
      JRVH, KM, GH, RW, and PLL all receive support from the National Heart, Lung, and Blood Institute. KM received personal fees from Fukuda Denshi unrelated to the submitted work. No other financial disclosures were reported.

      CRediT AUTHOR STATEMENT

      Jeremy R. Van't Hof: Conceptualization, Methodology, Writing - original draft. Wendy Wang: Data curation, Formal analysis. Kunihiro Matsushita: Methodology, Writing - review & editing. Gerardo Heiss: Writing - review & editing. Aaron R. Folsom: Writing - review & editing. Rachel Widome: Writing - review & editing. Pamela L. Lutsey: Conceptualization, Supervision, Writing - review & editing.

      Appendix. SUPPLEMENTAL MATERIAL

      REFERENCES

        • Fowkes FG
        • Rudan D
        • Rudan I
        • et al.
        Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis.
        Lancet. 2013; 382: 1329-1340https://doi.org/10.1016/S0140-6736(13)61249-0
        • Diehm C
        • Allenberg JR
        • Pittrow D
        • et al.
        Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease.
        Circulation. 2009; 120: 2053-2061https://doi.org/10.1161/CIRCULATIONAHA.109.865600
        • Ding N
        • Sang Y
        • Chen J
        • et al.
        Cigarette smoking, smoking cessation, and long-term risk of 3 major atherosclerotic diseases.
        J Am Coll Cardiol. 2019; 74: 498-507https://doi.org/10.1016/j.jacc.2019.05.049
        • Wang TW
        • Kenemer B
        • Tynan MA
        • Singh T
        • King B.
        Consumption of combustible and smokeless tobacco — United States, 2000–2015.
        MMWR Morb Mortal Wkly Rep. 2016; 65: 1357-1363https://doi.org/10.15585/mmwr.mm6548a1
        • Cornelius ME
        • Wang TW
        • Jamal A
        • Loretan CG
        • Neff LJ.
        Tobacco product use among adults — United States, 2019.
        MMWR Morb Mortal Wkly Rep. 2020; 69: 1736-1742https://doi.org/10.15585/mmwr.mm6946a4
        • Gupta R
        • Gurm H
        • Bartholomew JR.
        Smokeless tobacco and cardiovascular risk.
        Arch Intern Med. 2004; 164: 1845-1849https://doi.org/10.1001/archinte.164.17.1845
        • Yatsuya H
        • Folsom AR
        • Investigators ARIC
        Risk of incident cardiovascular disease among users of smokeless tobacco in the atherosclerosis risk in communities (ARIC) study.
        Am J Epidemiol. 2010; 172: 600-605https://doi.org/10.1093/aje/kwq191
        • Henley SJ
        • Thun MJ
        • Connell C
        • Calle EE.
        Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States).
        Cancer Causes Control. 2005; 16: 347-358https://doi.org/10.1007/s10552-004-5519-6
        • Wright JD
        • Folsom AR
        • Coresh J
        • et al.
        The ARIC (atherosclerosis risk in communities) study: JACC focus Seminar 3/8.
        J Am Coll Cardiol. 2021; 77: 2939-2959https://doi.org/10.1016/j.jacc.2021.04.035
        • Piano MR
        • Benowitz NL
        • Fitzgerald GA
        • et al.
        Impact of smokeless tobacco products on cardiovascular disease: implications for policy, prevention, and treatment: a policy statement from the American Heart Association.
        Circulation. 2010; 122: 1520-1544https://doi.org/10.1161/CIR.0b013e3181f432c3
        • Vidyasagaran AL
        • Siddiqi K
        • Kanaan M.
        Use of smokeless tobacco and risk of cardiovascular disease: A systematic review and meta-analysis.
        Eur J Prev Cardiol. 2016; 23: 1970-1981https://doi.org/10.1177/2047487316654026
      1. FDA permits marketing of E-cigarette products, marking first authorization of its kind by the agency. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-e-cigarette-products-marking-first-authorization-its-kind-agency. Updated December 12, 2021. Accessed September 27, 2022.

      2. FDA denies authorization to market JUUL products. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-denies-authorization-market-juul-products. Updated June 23, 2022. Accessed September 27, 2022.

        • Pechacek TF.
        Can e-cigarettes help adults who smoke successfully quit all combusted tobacco products?.
        JAMA Netw Open. 2021; 4e2130924https://doi.org/10.1001/jamanetworkopen.2021.30924
        • Agaku IT
        • King BA.
        Validation of self-reported smokeless tobacco use by measurement of serum cotinine concentration among U.S. adults.
        Am J Epidemiol. 2014; 180: 749-754https://doi.org/10.1093/aje/kwu182